
Invizius
Improving patient outcomes on dialysis and other extra-corporeal treatments.
Date | Investors | Amount | Round |
---|---|---|---|
investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor investor investor investor investor | €0.0 | round | |
investor investor investor investor investor investor investor investor investor | €0.0 | round | |
investor | €0.0 | round | |
* | £950k Valuation: £26.5m | Early VC | |
Total Funding | 000k |
Related Content
Invizius Limited, operating under the trading name Invizius, focuses on enhancing the safety and efficacy of dialysis treatments for patients with chronic kidney disease (CKD). The company operates in the healthcare sector, specifically targeting nephrology and renal replacement therapies. Invizius collaborates with key opinion leaders in the fields of the complement system, nephrology, and renal replacement therapies to develop its products. The company's primary clients include healthcare providers and institutions that offer dialysis treatments. Invizius generates revenue through the development and sale of its proprietary technologies and products aimed at reducing complications associated with dialysis. The company has secured over £2 million in competitive grant funding to support its technology and product development initiatives.
Keywords: dialysis, chronic kidney disease, nephrology, renal replacement, healthcare, safety, efficacy, technology, product development, grant funding.